Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network for Prevention Trials 012

Susan H. Eshleman, Laura A. Guay, Anthony Mwatha, Elizabeth Brown, Philippa Musoke, Francis Mmiro, J. Brooks Jackson

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Objective: To compare the rate of mother-to-child transmission (MTCT) in women with subtype A versus D HIV-1 who received single-dose nevirapine (NVP). Methods: The MTCT rates were compared in women with subtype A versus D at birth and at 8 weeks and 18 months of age of the infants. The rate of late MTCT (after 8 weeks of age) was also analyzed. Results: HIV-1 subtypes were determined for 300 of 306 women who received NVP in the HIV Network for Prevention Trials 012 study (158 women with subtype A and 105 women with subtype D). Infant infection status was known for 297 women. The cumulative rate of MTCT at 18 months was 13.2% for subtype A and 18.3% for subtype D (P = 0.34). The rate of late transmission was 3.8% for subtype A and 7.6% for subtype D (P = 0.28). Maternal baseline viral load was a significant predictor of MTCT, but maternal baseline CD4 cell count and subtype were not. Conclusions: No significant difference was observed in the rate of MTCT in women with subtype A versus D. There was a trend toward a higher rate of MTCT among women with subtype D, however, which was also apparent among women whose infants were infected after 8 weeks of age.

Original languageEnglish (US)
Pages (from-to)593-597
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume39
Issue number5
StatePublished - Aug 15 2005

Keywords

  • HIV-1
  • Mother-to-child transmission
  • Nevirapine
  • Subtype
  • Uganda

Fingerprint

Dive into the research topics of 'Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network for Prevention Trials 012'. Together they form a unique fingerprint.

Cite this